ProCAID: A randomized double-blind phase II clinical trial of capivasertib (C) in combination with docetaxel and prednisolone chemotherapy (DP) in metastatic castration-resistant prostate cancer (mCRPC).

Simon J. Crabb(University of Southampton), Robert J. Jones(Beatson West of Scotland Cancer Centre), Amy Whitehead(University Hospital Southampton NHS Foundation Trust), Ellice Marwood(University Hospital Southampton NHS Foundation Trust), Amit Bahl(At Bristol), Karen Martin(University Hospital Southampton NHS Foundation Trust), Charlotte Westbury(Institute of Cancer Research), Josh Northey(University Hospital Southampton NHS Foundation Trust), Satish Kumar(Singleton Hospital), Tony Elliott(The Christie Hospital), Emily Shaw(University Hospital Southampton NHS Foundation Trust), Alison Birtle(University of Lancashire), Santhanam Sundar(Nottingham University Hospitals NHS Trust), Vincent Khoo(The University of Texas MD Anderson Cancer Center), Gareth Griffiths(NIHR Evaluation Trials and Studies Coordinating Centre), Denise Dunkley(University Hospital Southampton NHS Foundation Trust), Michelle Light(University Hospital Southampton NHS Foundation Trust), Nichola Downs(University Hospital Southampton NHS Foundation Trust), Satinder Jagdev(Leeds Teaching Hospitals NHS Trust), Angus Robinson(Royal Sussex County Hospital)
Journal of Clinical Oncology
May 20, 2020
10.1200/jco.2020.38.15_suppl.5520
Cited by 2

Related Papers

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k